Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 339, Issue 1-2, Pages 223-225Publisher
ELSEVIER
DOI: 10.1016/j.jns.2014.01.035
Keywords
Devic's disease; Neuromyelitis optica; NMO; AQP4; Aquaporin-4; Natalizumab
Categories
Funding
- NHS National Specialised Commissioning Group for Neuromyelitis Optica
- NIHR Oxford Biomedical Research Centre
- Novartis
- Merk Serono
- TEVA
- Biogen
- Bayer Schering
- Bayer-Schering
- Biogen-Idec
- Merck-Serono
Ask authors/readers for more resources
Natalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spinal demyelinating syndrome, negative for aquaporin-4 antibodies, who experienced a catastrophic brain relapse shortly after a single dose of natalizumab, highlighting that MS immunomodulatory drugs may worsen demyelination in patients with seronegative NMO and atypical MS/NMO overlap syndromes even if they are aquaporin-4 antibody negative. We summarise the treatments considered safe and effective in NMO, and those with potential to exacerbate disease. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available